STRO Quote, Financials, Valuation and Earnings

Mersana Therapeutics has a net margin of -572.62% compared to Sutro Biopharma's net margin of -86.29%. Sutro Biopharma's return on equity of -99.41% beat Mersana Therapeutics's return on equity of -533.43%.

Sutro Biopharma has a consensus price target of $7.89, signalling upside risk potential of 873.82%. On the other hand Mersana Therapeutics has an analysts' consensus of $4.71 which suggests that it could grow by 914.04%. Given that Mersana Therapeutics has higher upside potential than Sutro Biopharma, analysts believe Mersana Therapeutics is more attractive than Sutro Biopharma.

Sutro Biopharma has a beta of 1.219, which suggesting that the stock is 21.934% more volatile than S&P 500. In comparison Mersana Therapeutics has a beta of 1.667, suggesting its more volatile than the S&P 500 by 66.661%.

Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mersana Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma pays -- of its earnings as a dividend. Mersana Therapeutics pays out -- of its earnings as a dividend.

Sutro Biopharma quarterly revenues are $8.5M, which are smaller than Mersana Therapeutics quarterly revenues of $16.4M. Sutro Biopharma's net income of -$48.8M is lower than Mersana Therapeutics's net income of -$14.1M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while Mersana Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 0.36x versus 1.41x for Mersana Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Palisade Bio has a net margin of -572.62% compared to Sutro Biopharma's net margin of --. Sutro Biopharma's return on equity of -99.41% beat Palisade Bio's return on equity of --.

Sutro Biopharma has a consensus price target of $7.89, signalling upside risk potential of 873.82%. On the other hand Palisade Bio has an analysts' consensus of $20.00 which suggests that it could grow by 1900%. Given that Palisade Bio has higher upside potential than Sutro Biopharma, analysts believe Palisade Bio is more attractive than Sutro Biopharma.

Sutro Biopharma has a beta of 1.219, which suggesting that the stock is 21.934% more volatile than S&P 500. In comparison Palisade Bio has a beta of 1.495, suggesting its more volatile than the S&P 500 by 49.511%.

Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palisade Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma pays -- of its earnings as a dividend. Palisade Bio pays out -- of its earnings as a dividend.

Sutro Biopharma quarterly revenues are $8.5M, which are larger than Palisade Bio quarterly revenues of --. Sutro Biopharma's net income of -$48.8M is lower than Palisade Bio's net income of -$3.5M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while Palisade Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 0.36x versus -- for Palisade Bio. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -572.62% compared to Sutro Biopharma's net margin of 24.22%. Sutro Biopharma's return on equity of -99.41% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Sutro Biopharma has a consensus price target of $7.89, signalling upside risk potential of 873.82%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 38.42%. Given that Sutro Biopharma has higher upside potential than Regeneron Pharmaceuticals, analysts believe Sutro Biopharma is more attractive than Regeneron Pharmaceuticals.

Sutro Biopharma has a beta of 1.219, which suggesting that the stock is 21.934% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. Sutro Biopharma pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Sutro Biopharma quarterly revenues are $8.5M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Sutro Biopharma's net income of -$48.8M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 0.36x versus 5.40x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of -572.62% compared to Sutro Biopharma's net margin of -549.33%. Sutro Biopharma's return on equity of -99.41% beat Voyager Therapeutics's return on equity of -21.07%.

Sutro Biopharma has a consensus price target of $7.89, signalling upside risk potential of 873.82%. On the other hand Voyager Therapeutics has an analysts' consensus of $16.10 which suggests that it could grow by 312.82%. Given that Sutro Biopharma has higher upside potential than Voyager Therapeutics, analysts believe Sutro Biopharma is more attractive than Voyager Therapeutics.

Sutro Biopharma has a beta of 1.219, which suggesting that the stock is 21.934% more volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.991, suggesting its less volatile than the S&P 500 by 0.87699999999999%.

Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

Sutro Biopharma quarterly revenues are $8.5M, which are larger than Voyager Therapeutics quarterly revenues of $6.3M. Sutro Biopharma's net income of -$48.8M is lower than Voyager Therapeutics's net income of -$34.5M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 0.36x versus 2.81x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.